Efficacy of Retreatments With Intravitreal Bevacizumab
Evaluation of Efficacy of Intravitreal Bevacizumab Retreatments
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Hugo Quiroz-Mercado, MD
- Phone Number: 1171 525510841400
- Email: retinamex@yahoo.com
Study Contact Backup
- Name: Veronica A Kon-Jara, MD
- Phone Number: 1172 525510841400
- Email: veronicakon@yahoo.com
Study Locations
-
-
DF
-
Mexico DF, DF, Mexico, 04030
- Asociación Para Evitar la Ceguera en México
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
* Any visual acuity
- OCT: Central foveal thickness greater than 300 u or with evidence of subretinal fluid.
- Active angiogram leakage
Exclusion Criteria:
* Basal Inflammatory disease
- Endoftalmitis history
- Lesions bigger than 5400 u or with scarring greater than 50% of lesion.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Best corrected visual acuity, OCT foveal thickness and fluorescein angiogram
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Veronica Kon-Jara, MD, Asociación Para Evitar la Ceguera en México
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Uveal Diseases
- Choroid Diseases
- Metaplasia
- Macular Degeneration
- Choroidal Neovascularization
- Neovascularization, Pathologic
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
Other Study ID Numbers
- APEC-0012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.